Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NT Life Sciences is a biopharmaceutical joint venture established by NantWorks and Merz Pharma to develop and commercialize innovative therapies in the fields of neurology and aesthetics. The company's primary focus is on the development of NT-0201 (incobotulinumtoxinA), a botulinum toxin type A marketed as Xeomin, for expanded indications such as sialorrhea. Additionally, NT Life Sciences is advancing NT-0502, a novel small molecule muscarinic antagonist designed to treat chronic sialorrhea by reducing excessive salivation. The company leverages the combined expertise of Merz in neurotoxin research and NantWorks in molecular medicine and data-driven healthcare. NT Life Sciences also operates a joint venture with The Times Group to bring advanced healthcare technologies to the Indian market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NT Life Sciences.